Reaffirms FY25 SG&A expenses view $50M-$60M excluding share-based compensation. Reaffirms FY25 share-based compensation expenses view $18M-$20M; and Non-GAAP Net Income from Operations and Cash Burn in 2025 to be similar to levels incurred in 2024. Both Non-GAAP Net Income from Operations and Cash Burn guidance metrics exclude one-time, non-recurring Revenue and Income items incurred throughout 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Theravance Biopharma price target raised to $25 from $24 at BTIG
- Theravance Biopharma Gains Milestone Payment from Viatris
- Theravance Biopharma announces Viatris approval for Yupelri in China
- Theravance Biopharma initiated with a Buy at JonesResearch